Elite Pharmaceuticals Inc (ELTP)

[NASDAQ2020]

Elite's Multi-Billion Dollar Platform:
Short to mid term products are entering an IMS market value
of $6 + Billion Dollar$
Bright future ahead for ELTP
Elite's Current Marketed Products and Pipeline is growing rapidly ! Fully developed its worth Billion$
Start watching for the undisclosed drug filings.
$$$$$$$$$$$$
Elite working on 7 AD opiods concurrently

$Generic Products$$

Commercial Product
Branded Product Equivalent
Therapeutic Category

1. Hydromorphone Hydrochloride
8 mg Tablets
Dilaudid®
Pain

2. Naltrexone Hydrochloride
50 mg Tablets
Revia®
Opioid Antagonist

3. Phentermine HCl
37.5 mg Tablets
Adipex-P®
Bariatric

4. Phentermine HCI
15 mg and 30 mg Capsules
Adipex-P®
Bariatric

5. Phendimetrazine Tartrate
35 mg Tablets, USP
Bontril®
Bariatric

6. Isradipine
2.5 mg and 5 mg Capsules
N/A
Cardiovascular

7. Hydroxyzine HCI
10 mg, 25 mg, 50 mg Tablets
Atarax®, Vistaril®
Antihistamine

8. Dantrolene Sodium
25 mg, 50 mg and 100 mg Capsules *
Dantrium®
Skeletal Muscle Relaxant

9. Loxapine
5 mg, 10 mg, 25 mg, 50 mg Capsules *
N/A
Antipsychotic

10. Additional Approved ANDA's *
Undisclosed
Undisclosed
* pending manufacturing site transfer

11. Trimipramine

$BRANDED PRODUCTS$$
Commercial Product
Therapeutic Category
Partner

12. Lodrane D®
OTC Allergy
Valeant Pharmaceuticals International, Inc.


$CONTRACT MANUFACTURING$$
Commercial Product
Branded Product Equivalent
Therapeutic Category
Partner

13. Methadone Hydrochloride
10 mg Tablets
Dolophine®
Pain
Ascend Laboratories, LLC


$GENERIC PIPELINE$$

Programs Under Development
Branded Product Equivalent
Therapeutic Category
Development Stage

14. ELI-300 Opioid
Undisclosed
Pain
Early Development

15. ELI-301 Opioid
Undisclosed
Pain
Early Development

16. Oxycodone HCl and Acetaminophen, USP 325 mg
5 mg, 7.5 mg, 10 mg Tablets
Percocet
Pain
Pending FDA Approval

17. Hydrocodone bitartrate and Acetaminophine tablets, 2.5mg/325mg, 5mg/325mg, 7.5mg/325mg and 10mg/325mg tablets
Norco
Pain
Pending FDA Approval

18. Elite/SunGen Generic #1
Undisclosed
CNS Stimulant
In Development

19. Elite/SunGen Generic #2
Undisclosed
CNS Stimulant
In Development

20. Elite/SunGen Generic #3
Undisclosed
Beta-Blocker
In Development

21. Elite/SunGen Generic #4
Undisclosed
Beta-Blocker
In Development

22. Elite/SunGen Generic #5
Undisclosed
Anti-depressant
In Development

23. Elite/SunGen Generic #6
Undisclosed
Antibiotic #1
In Development

24. Elite/SunGen Generic #7
Undisclosed
Antibiotic #2
In Development

25. Elite/SunGen Generic #8
Undisclosed
Antispasmodic
In Development

26. Generic Troxyca
Pain

27. Generic Embeda
Pain

28. Generic OxyContin

29. Generic Opana Oxymorphone
Pain


$BRANDED PIPELINE$$

Development Stage
Partner

30. $equestOx™ (ELI-200) Opioid
Pain
NDA Submitted
PDUFA date: July 14, 2016
Epic Pharma LLC

31. ELI-201 ER Opioid
Troxyca equivalent
Pain
Pivotal Bio-equivalence

32. ELI-202 Opioid
Pain
Pivotal Bio-equivalence

33. ELI-216 Opioid ER 24hr (once/day)
Pain
Process Development

34. ELI-400 Opioid
Pain
Process Development

35. ELI-500 Opioid
Pain
Process Development

36. ELI-501 Opioid
Pain
Early Development

37. ELI-600 Opioid
Pain
Process development ELTP

38. Chinese ADF opiod

39. Canadian ADF opiod

40. European ADF opiod
$ELTP


ELTP



Sure Trader - Start Trading Stocks & Options with only $500